Unicancer

This phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…

This phase 3 trial is testing whether adding a three-month course of FOLFOX4s chemotherapy after short-course radiotherapy improves outcomes compared to radiotherapy alone in adults aged 75 and older with locally advanced rectal cancer. The study aims to see if the combination ca…

This study tests whether a special scan (SPECT-CT) can show which side of the neck needs radiation in people with oropharyngeal cancer. Currently, both sides are treated to prevent hidden cancer spread, but this causes more side effects. The trial will enroll 128 patients to see …

This study tests whether a blood test can identify people with advanced lung cancer who can be treated with immunotherapy alone instead of chemotherapy plus immunotherapy. The trial enrolls 275 adults with high PD-L1 levels and a low inflammation blood score. The goal is to see i…

This phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…

This phase 2 trial tests the drug zanzalintinib in people whose adenoid cystic carcinoma (a rare salivary gland cancer) has returned or spread. Despite initial surgery and radiation, about half of patients experience recurrence, and current treatments offer limited benefit. Parti…

This Phase 3 trial tests whether giving chemotherapy directly into the liver artery (HAI) after surgery can prevent cancer from coming back in patients with colorectal cancer that spread to the liver. About 272 high-risk patients will receive either standard IV chemo or HAI chemo…

This phase 2 trial tests whether adding the immune-boosting drug ivonescimab to standard chemotherapy (FOLFIRI) helps people with advanced colorectal cancer live longer without their cancer growing. It compares this new combination to the current standard of FOLFIRI plus bevacizu…

This study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…

This study tests whether annual liquid biopsies (from blood, urine, stool, and vaginal swabs) can safely replace colonoscopies every 18 months for people with Lynch syndrome. 2,000 participants will be split into two groups: one gets standard care (colonoscopy every 18 months), t…

This study tests a special PET scan that uses a radioactive tracer to track a protein called HER2 in the body. It aims to see if this imaging can predict how well a targeted cancer drug (T-DXd) works in 30 people with advanced breast cancer. The goal is to potentially replace inv…

This study aims to see if a simple blood test can find HPV-related oropharyngeal cancer early in men aged 50 and older who have no symptoms. Researchers will check blood for two markers of HPV and then follow up with those who test positive to find and treat any tumors. If succes…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…